Market Indices
Sector Heatmap
CTNM — Contineum Therapeutics, Inc. Class A Common Stock
NasdaqContineum Therapeutics, Inc. Class A Common Stock
- O
- 13.15
- H
- 13.24
- L
- 12.59
- V
- 794.23K
CTNM — Latest News & Headlines
13 StoriesA 4,170-share sale is proposed by Contineum Therapeutics (CTNM) officer Daniel Lorrain. - Stock Titan
A 4,170-share sale is proposed by Contineum Therapeutics (CTNM) officer Daniel Lorrain. Stock Titan
Market Movers | Winners: PACB, MNKD, CTNM | Losers: LQDA, GLAS, QNC - Trefis
Market Movers | Winners: PACB, MNKD, CTNM | Losers: LQDA, GLAS, QNC Trefis
RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk - Yahoo Finance
RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk Yahoo Finance
(CTNM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
(CTNM) Price Dynamics and Execution-Aware Positioning Stock Traders Daily
Stifel reiterates Contineum Therapeutics stock rating at buy - Investing.com
Stifel reiterates Contineum Therapeutics stock rating at buy Investing.com
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading - The Globe and Mail
Contineum Therapeutics, Inc. Class A (CTNM) Receives a Buy from JonesTrading The Globe and Mail
Stifel Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Stifel Maintains Contineum Therapeutics(CTNM.US) With Buy Rating, Maintains Target Price $28 Moomoo
RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
RBC Cuts Price Target on Contineum Therapeutics to $21 From $23, Keeps Outperform, Speculative Risk marketscreener.com
Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from JonesTrading - The Globe and Mail
Contineum Therapeutics, Inc. Class A (CTNM) Gets a Buy from JonesTrading The Globe and Mail
Goldman Sachs initiates coverage on Contineum Therapeutics stock - Investing.com
Goldman Sachs initiates coverage on Contineum Therapeutics stock Investing.com
Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
Stifel Nicolaus Keeps Their Buy Rating on Contineum Therapeutics, Inc. Class A (CTNM) The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM) - The Globe and Mail
RBC Capital Sticks to Their Buy Rating for Contineum Therapeutics, Inc. Class A (CTNM) The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wall Street Analysts Are Bullish on Top Healthcare Picks The Globe and Mail